WARS2

Across TCGA pan-cancer cohorts, WARS2 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated WARS2 data layer compared with 21 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in colon adenocarcinoma (COAD), where higher WARS2 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated WARS2 expression acts as an unfavorable survival marker, although some lineages such as COAD and PDAC show a favorable association.

COAD, PDAC, and LSCC are the cancer types where WARS2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
COAD	DFS	Median	II,III,IV	1.000	0.914	.015	48	view →
PDAC	OS	Quartile	All	0.709	0.436	.006	5	view →
LSCC	OS	Tertile	II,III,IV	0.959	0.753	.022	4	view →
LUAD	DFS	Tertile	II,III,IV	0.193	0.665	.042	3	view →
CCRCC	DFS	Quartile	II,III,IV	0.377	0.777	.017	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

WARS2–COAD (DFS)

Open the COAD breakdown →